BioStockInfo · catalyst calendar
/
← Catalyst calendar

AIM biotech catalysts & pipeline

AIM IMMUNOTECH INC · Data as of 2026-09-08

Upcoming catalysts

Durvalumab (Imfinzi) and Rintatolimod (Ampligen) — Full data

2026

Erasmus MC expects that detailed data will be published later this year.
Source filing

Durvalumab (Imfinzi) and Rintatolimod (Ampligen) — Full data

January 2027

Collection of additional secondary endpoint data including progression-free survival, time to disease progression and overall survival is expected to be completed in January 2027.
Source filing

Durvalumab (Imfinzi) and Rintatolimod (Ampligen) — Topline data

Q1 2027

We anticipate DURIPANC data on clinical benefit in Q1 2027 and on Overall Survival – the gold standard data point in oncology – in Q3 2027.
Source filing

Durvalumab (Imfinzi) and Rintatolimod (Ampligen) — Topline data

Q3 2027

We anticipate DURIPANC data on clinical benefit in Q1 2027 and on Overall Survival – the gold standard data point in oncology – in Q3 2027.
Source filing

Explore the free biotech catalyst calendar